Theraclion Pursues Its Strategy and Announces Its 2023 Revenue
January 29 2024 - 1:45PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE),
an innovative company developing a scalable robotic platform for
non-invasive focused ultrasound therapy (HIFU), announces today
the continued execution of its value creation strategy and its
turnover for 2023. One of its mainstays, sale of consumables for
varicose veins, is up by a substantial 61%.
Access to the US market for SONOVEIN®: progress in the
pivotal study
The process of accessing the vast US market is proceeding
according to plan, with more than a third of patients already
treated as part of the pivotal clinical trial that began in the US
in October 2023. Two other treatment sites included in this study,
located in Europe, have also since opened. Treatment of patients
enrolled in the clinical trial will continue during the first half
of 2024. Marketing authorization in the US is envisaged for early
2026.
Strategic partnership with Furui: first milestones
achieved
Theraclion SA and Furui have achieved new milestones in the
context of their partnership with a view to conquering the Chinese
market. The restructuring of the Theraclion China joint venture is
well underway, with technical and operational collaborations
already active, following an ambitious action plan. These efforts
have led to the invoicing of €2,000K in license fees to Theraclion
China for Echopulse® and SONOVEIN® at the end of 2023.
Turnover up 48% and sales of varicose vein consumables up
61%
Theraclion SA recorded a turnover of €1,822K in 2023
representing an increase of 48%. In addition, the inclusion of
€2,000K in revenue from license fees granted to Theraclion China
brings total operating revenues to €3,825K, an increase of 180%
compared to 2022.
Sales of consumables, most of which are recurrent, rose by 41%
overall, driven by strong growth in varicose vein indication, up
61% since 2022. In line with its strategy, Theraclion is making
SONOVEIN® available to reference centers involved in development of
treatment protocols while also integrating it into their commercial
practices. Theraclion's performance in 2023 demonstrates these
treatment centers’ positive uptake of its solutions.
Additionally, system sales were up 58%, standing at €1,204K.
Turnover in K€
2023
2022
Variation
Sale of systems
1 204
764
58%
Sale of consumables
506
360
41%
Sale of services
112
112
1%
Total turnover
1 822
1 235
48%
Including veins
1 200
940
28%
Including breast and thyroid
622
295
111%
Other operating revenue
3
132
-98%
Licenses
2 000
-
-
Operating revenue total
3 825
1 367
180%
The various intermediate objectives, both for the clinical study
with a view to FDA authorization in the US, and for the partnership
with Furui to penetrate the Chinese market, have so far all been
achieved.
Moreover, the study led by Prof. David Brenin at the University
of Virginia Cancer Center aiming at proving the efficacy of focused
ultrasound in the treatment of breast cancer is continuing. This
potentially offers Theraclion a very significant additional
value-enhancing outlet.
About Theraclion
Theraclion is a French MedTech company committed to developing a
non-invasive alternative to surgery through innovative use of
focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) does not require
incisions or an operating theater, leaves no scars, and enables
patients to return to their daily activities immediately.
Echotherapy, as the HIFU treatment method is called, concentrates
therapeutic ultrasounds to an internal focal point from outside of
the body.
Theraclion has developed two CE-marked robotic platforms
delivering echotherapy: SONOVEIN® for varicose veins and ECHOPULSE®
for breast fibroadenoma and thyroid nodules. Both of them have the
potential to replace millions of surgical procedures every
year.
Based in Malakoff (Paris), the Theraclion team is made up of 30
people, most of them involved in technological and clinical
development.
For more information, please visit
www.theraclion.com or www.echotherapy.com
and follow the LinkedIn account
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240129141191/en/
Theraclion Martin Deterre Chief Executive Officer
contact@theraclion.com
Theraclion (EU:ALTHE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Theraclion (EU:ALTHE)
Historical Stock Chart
From Aug 2023 to Aug 2024